Thailand · Delayed Price · Currency is THB Bumrungrad Hospital PCL Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw modest revenue growth, strong EBITDA margin, and robust Middle East contributions, while Thai patient revenue declined amid economic headwinds. Outlook for Q2 is slightly improved, with continued focus on cost control, new clinic openings, and expansion of advanced medical services.
-
Q1 2026 delivered modest revenue growth, record EBITDA margin, and strong non-Thai patient performance, especially from the Middle East. New projects in Phuket and Bangladesh are progressing, while Centers of Excellence and specialty services saw robust growth.
Fiscal Year 2025
-
Q3 2025 saw robust earnings growth driven by international patients, especially from the Middle East and South Asia, offsetting declines in Thai and Indochina segments. Record EBITDA and net profit margins were achieved, with strong specialty center performance and a positive outlook for Q4.
-
Q2 2025 revenue declined 3.6% year-over-year to THB 6,104 million, but EBITDA margin hit a record 41.6% due to strong cost control. Middle East patient volumes rebounded sequentially, while insurance revenue grew 12% YTD. Outlook for 2H 2025 is positive, with Q3 revenue guided up 3%-5%.
-
Q1 2025 revenue declined 5.6% year-over-year, mainly due to a 30% drop in Middle East revenue from Ramadan's early timing, while Thai patient revenue grew 1.2%. EBITDA and net profit both fell 12.6%, but cash and investments rose to THB 16 billion.
Fiscal Year 2024
-
Record-high net profit and EBITDA margins were achieved in 2024, with 11% EPS growth despite a THB 1.2 billion revenue loss from Kuwait and UAE, offset by strong gains in Qatar, Thai, and expat segments. A record THB 5 per share dividend is proposed, and VitalLife delivered double-digit growth.
-
Q3 2024 saw a 4.9% revenue decline and flat net profit, but margins remained strong due to cost control. Middle East patient revenue dropped sharply, while China and U.S. segments grew. CapEx plans and new projects, including the Phuket hospital, remain on track.
-
Q2 and 1H 2024 saw record margins and strong profit growth, driven by international diversification and cost control, despite a sharp drop in Kuwaiti patient revenue. Insurance and VitalLife segments posted robust gains, and a record interim dividend was declared.